TMCnet News

Robert Ingram Joins Regeneron Board of Directors [Professional Services Close - Up]
[April 16, 2014]

Robert Ingram Joins Regeneron Board of Directors [Professional Services Close - Up]


(Professional Services Close - Up Via Acquire Media NewsEdge) Regeneron Pharmaceuticals, Inc. announced that it has elected Robert A. Ingram to its Board of Directors.

According to a release, Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company, is retiring from the Board after nearly 26 years of service to Regeneron.

The Company noted that Ingram was nominated to become a member of Regeneron's Board by Sanofi. Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi gained the right to nominate a single independent director to the Regeneron Board of Directors when it reached 20 percent ownership of Regeneron's total outstanding common stock and Class A stock. Sanofi recently reached this threshold.



"Bob Ingram is an experienced leader with a distinguished career in the pharmaceutical industry," said P. Roy Vagelos, M.D., Chairman of the Regeneron Board of Directors. "We are extremely pleased to add his expertise, which spans many decades across many senior functions within the industry, to our Board." "I am delighted to be joining Regeneron at this exciting time in its history," said Ingram. "With three approved products, a broad pipeline of antibodies, and multiple near-term commercial opportunities, I look forward to helping Regeneron achieve its mission of delivering novel therapies to patients with unmet medical needs." Further, Ingram is a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to Hatteras, Ingram was Chief Executive Officer and Chairman of Glaxo/Wellcome. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching the mandatory retirement age of 60, Ingram was asked to serve as the Vice Chairman, Pharmaceuticals at GSK. He remained in this role until January 1, 2010, at which time he became Strategic Advisor to the CEO of GlaxoSmithKline Plc. Ingram serves as the Lead Director of Valeant Pharmaceuticals and Cree, Inc. He is also a member of the Board of Directors of Edwards Lifesciences Corp.

Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company, is retiring from the Board after nearly 26 years of outstanding service to Regeneron. Dr. Shooter has been a Professor at Stanford University School of Medicine since 1968 and was the founding Chairman of the Department of Neurobiology at Stanford University School of Medicine in 1975 and served as its Chairman until 1987. Dr. Shooter, a member of the National Academy of Sciences, is best known for characterizing the protein known as Nerve Growth Factor.


"Eric has been one of our longest serving non-employee directors and his dedication to Regeneron over the past 26 years has been deeply appreciated," said Dr. Vagelos. "We have valued Eric's leadership, intellect, and scientific acumen and would like to express our appreciation for his service." Regeneron is a science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

More information: www.regeneron.com.

((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved.

[ Back To TMCnet.com's Homepage ]